Bioavailability, Pharmacokinetics, and Analgesic Activity of Ketamine in Humans
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
The pharmacokinetics of ketamine in analgesic doses after intravenous, intramuscular, and oral administration was investigated in healthy volunteers. Plasma ketamine concentration-time curves were fitted by a two-compartment open model with a terminal half-life of 186 min. Absorption after intramuscular injection was rapid and the bioavailability was 93%. However, only 17% of an oral dose was absorbed because of extensive first-pass metabolism. Simultaneous measurements of the elevation of pain threshold in an ischemic exercise test showed a marked effect for 15-60 min after intramuscular injection, but little or no effect after the oral solution. Pain threshold elevation occurred at plasma ketamine concentrations above 160 ng/ml.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Regarding elimination of ketamine and its metabolites, the elimination half-life is between two to four hours, varying slightly with the route of administration”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Clements et al., 1982
Citations
Cites
A Simplex Method for Function Minimization
Nelder, J. A., & Mead, R. (1965) · The Computer Journal · doi:10.1093/comjnl/7.4.308 · Cited by 28,905
TESTING FOR SERIAL CORRELATION IN LEAST SQUARES REGRESSION. II
DURBIN, J., & WATSON, G. S. (1951) · Biometrika · doi:10.1093/biomet/38.1-2.159 · Cited by 3,619
Drugs and the Pharmaceutical Sciences
(2010) · Drugs and the pharmaceutical sciences · doi:10.1201/ihcdruphasci · Cited by 586
New Method for Calculating the Intrinsic Absorption Rate of Drugs
Loo, J. C. K., & Riegelman, S. (1968) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600570602 · Cited by 466
PHARMACOKINETICS AND ANALGESIC EFFECTS OF I.M. AND ORAL KETAMINE
GRANT, I. S., NIMMO, W. S., & CLEMENTS, J. A. (1981) · British Journal of Anaesthesia · doi:10.1093/bja/53.8.805 · Cited by 355
Self-citationPHARMACOKINETICS AND ANALGESIC EFFECT OF KETAMINE IN MAN
CLEMENTS, J. A., & NIMMO, W. S. (1981) · British Journal of Anaesthesia · doi:10.1093/bja/53.1.27 · Cited by 322
Self-citationKETAMINE INFUSIONS: PHARMACOKINETICS AND CLINICAL EFFECTS
IDVALL, J., AHLGREN, I., ARONSEN, K. F., & STENBERG, P. (1979) · British Journal of Anaesthesia · doi:10.1093/bja/51.12.1167 · Cited by 306
Influence of Route of Administration on Drug Availability
Rowland, M. (1972) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600610111 · Cited by 264
Pedersen, P. V. (1977) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061732 · Cited by 219
Ottaway, J. H. (1973) · Biochemical Journal · doi:10.1042/bj1340729 · Cited by 101
Research works printed but not linked: 9
- Wieber, 1975, Anaesthetist, 24, 260
- Clausen, 1975, Med. J., 49, 1437
- Harrison, 1943, Proc. Assoc. Res. Nerv. Ment. Dis., 23, 154
- Walle, 1970, Acta Pharm. Suec., 7, 389
- Durbin, 1950, Biometrika, 37, 409
- Gibaldi, 1979, Vol. 1, 232
- Rowland, 1972, ibid, 61, 70
- Gibaldi, 1971, ibid., 60, 624
- Pang, 1978, ibid., 67, 703
Cited by
Items 101–200 of 418
Dosing Ketamine for Pediatric Procedural Sedation in the Emergency Department
Dallimore, D., Herd, D. W., Short, T., & Anderson, B. J. (2008) · Pediatric Emergency Care · doi:10.1097/pec.0b013e318180fdb5 · Cited by 41
Ye, T., Bartlett, M. J., Schmit, M. B., Sherman, S. J., Falk, T., & Cowen, S. L. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00061 · Cited by 44
Pharmacokinetics and Pharmacology of Drugs Used in Children
Coté, C. J., Lerman, J., Ward, R. M., Lugo, R. A., & Goudsouzian, N. G. (2009) · Elsevier eBooks · doi:10.1016/b978-141603134-5.50010-x · Cited by 43
The Role of Ketamine, an NMDA Receptor Antagonist, in the Management of Pain
Łuczak, J., Dickenson, A. H., & Kotlińska–Lemieszek, A. (1995) · Progress in Palliative Care · doi:10.1080/09699260.1995.11746707 · Cited by 45
Ketamine—A Narrative Review of Its Uses in Medicine
Radvansky, B. M., Puri, S., Sifonios, A. N., Eloy, J. D., & Le, V. (2015) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000257 · Cited by 44
“Ninety percent of the drug is excreted through renal clearance; most is metabolized, but up to 4% can remain unchanged.(36) Renal clearance is 12–20 mL$min21$kg21.”
BackgroundUlbrich, F., Eisert, L., Buerkle, H., Goebel, U., & Schallner, N. (2016) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000000449 · Cited by 43
A meta-analysis of the effects of ketamine on suicidal ideation in depression patients
Shen, Z., Gao, D., Lv, X., Wang, H., & Yue, W. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02973-1 · Cited by 55
Drugs currently in Phase II clinical trials for cocaine addiction
Kim, J. H., & Lawrence, A. J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.915312 · Cited by 43
“Oral ketamine’s bioavailability is 20%, however, with a short half-life of 2 -- 3 h; ketamine has moderate-to-high risk of abuse especially via injection that preserves its bioavailability (93 -- 100%) [128].”
BackgroundSmith-Apeldoorn, S. Y., Veraart, J. K. E., Kamphuis, J., van Asselt, A. D. I., Touw, D. J., aan het Rot, M., & Schoevers, R. A. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2359-1 · Cited by 39
Quibell, R., Fallon, M., Mihalyo, M., Twycross, R., & Wilcock, A. (2015) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2015.06.002 · Cited by 44
Yu, Z., Han, Y., Hu, D., Chen, N., Zhang, Z., Chen, W., Xue, Y.-X., Meng, S., Lü, L., Zhang, W., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01495-w · Cited by 41
“The anti-depressant effect of ketamine is mediated by Neurocan of PNNs in adolescent rats Ketamine is a non-competitive NMDA receptor blocker known for its rapid anti-depressant effect [36, 54], and it has a relatively short half-life of 2–3 h [55].”
BackgroundAnaesthetic agents in adult day case surgery
Pollard, B. J., Elliott, R. A., & Moore, E. W. (2005) · European Journal of Anaesthesiology · doi:10.1017/s0265021503000012 · Cited by 37
Robison, R., Lafrance, A., Brendle, M., Smith, M., Moore, C., Ahuja, S., Richards, S., Hawkins, N., & Strahan, E. (2022) · Journal of Eating Disorders · doi:10.1186/s40337-022-00588-9 · Cited by 36
“dissociation and slight increases in blood pressure which have been observed to resolve upon elimination of ketamine from the system [1, 7, 8].”
BackgroundRole of the mesolimbic dopamine pathway in the antidepressant effects of ketamine
Cardona-Acosta, A. M., & Bolaños‐Guzmán, C. A. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109374 · Cited by 38
EFFECTS OF PROTEIN CALORIE MALNUTRITION ON THE PHARMACOKINETICS OF KETAMINE IN RATS
Williams, M. L., Mager, D. E., Parenteau, H. I., Gudi, G. S., Tracy, T. S., Mulheran, M., & Wainer, I. W. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.8.786 · Cited by 40
“The fraction of KET absorbed into the blood stream following i.m. injection was assumed to be complete (Clements et al., 1982), and total systemic clearance was secondarily calculated, where Cl kel VKET.”
MethodWillert, R. P., Delaney, C. M., Kelly, K. G., Sharma, A., Aziz, Q., & Hobson, A. R. (2007) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2006.00890.x · Cited by 37
Kuhlen, R., Max, M., Dembinski, R., Terbeck, S., Jürgens, E., & Rossaint, R. (2005) · European Journal of Anaesthesiology · doi:10.1017/s0265021503000024 · Cited by 34
Ridenour, T. R., Warner, D. S., Todd, M. M., & Baker, M. T. (1991) · Brain Research · doi:10.1016/0006-8993(91)91742-j · Cited by 32
The role of serotonin neurotransmission in rapid antidepressant actions
Pehrson, A. L., Roberts, D., Khawaja, A., & McNair, R. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06098-5 · Cited by 37
“This notion is critical for explaining how ketamine, which has a very short half-life in humans (about 3 h; Clements et al. 1982) and rodents (45–60 min; Saland and Kabbaj 2018), can have antidepressant effects that long outlast its presence in the brain, in some cases, lasting a week after administration (Zarate et a…”
BackgroundS-ketamine concentrations are greatly increased by grapefruit juice
Peltoniemi, M. A., Saari, T. I., Hagelberg, N. M., Laine, K., Neuvonen, P. J., & Olkkola, K. T. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1214-9 · Cited by 32
Intranasal Ketamine and Its Potential Role in Cancer‐Related Pain
Singh, V., Gillespie, T. W., & Harvey, R. D. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2090 · Cited by 34
Thomson, I. A., Fitch, W., Campbell, D., & Watson, R. D. (1988) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.1988.tb02677.x · Cited by 32
Acute and Chronic Effects of Ketamine on Semantic Priming: Modeling Schizophrenia?
Stefanovic, A., Brandner, B., Klaassen, E. B., Cregg, R., Nagaratnam, M., Bromley, L. M., Das, R., Rossell, S. L., Morgan, C. J. A., & Curran, H. V. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31819a4b91 · Cited by 32
“The program uses a boluselimination-transfer infusion scheme based on the Clements pharmacokinetic model.(24) A steady state of predicted plasma ketamine/placebo concentration according to the model was achieved in a period of 12 minutes.”
MethodEffects of different doses of oral ketamine for premedication of children
Turhanoğlu, S., Kararmaz, A., Özyilmaz, M. A., Kaya, S., & Tok, D. (2003) · European Journal of Anaesthesiology · doi:10.1097/00003643-200301000-00010 · Cited by 31
Arylcyclohexylamine Derivatives: Pharmacokinetic, Pharmacodynamic, Clinical and Forensic Aspects
Pelletier, R., Daré, B. L., Bouëdec, D. L., Kernalléguen, A., Ferron, P., Morel, I., & Gicquel, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415574 · Cited by 34
“The primary metabolic pathway gives rise to norketamine (an active metabolite) and hydroxylated derivatives [45,46].”
BackgroundParise, E. M., Parise, L. F., Sial, O. K., Cardona-Acosta, A. M., Gyles, T. M., Juarez, B., Chaudhury, D., Han, M., Nestler, E. J., & Bolaños‐Guzmán, C. A. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.002 · Cited by 33
Ilkiw, J. E., Pascoe, P. J., & Tripp, L. D. (2003) · American Journal of Veterinary Research · doi:10.2460/ajvr.2003.64.907 · Cited by 30
Effects of different doses of oral ketamine for premedication of children
Turhanoğlu, S., Kararmaz, A., Özyilmaz, M. A., Kaya, S., & Tok, D. (2005) · European Journal of Anaesthesiology · doi:10.1017/s0265021503000103 · Cited by 29
Glue, P., Russell, B., & Medlicott, N. J. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03047-z · Cited by 33
“…and route of administration Formulation/route Enant Dose (mg/kg) ABA K:NK ratio Tmax Dissociation ↑BP Paper Solution/IV Rac 0.25 100% - 0 - - Clements 1982 [15] Rac 3 100% 7.0 0 - - Malinovsky 1996 [16] Rac 0.3 100% - 0 - - Yanagihara 2002 [17] Rac 0.14 100% 7.77 1 - - Chong 2009 [18] Rac…”
InfluentialAbuhelwa, A. Y., Somogyi, A. A., Loo, C. K. A., Glue, P., Barratt, D. T., & Foster, D. J. R. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2640 · Cited by 32
“administration.(25) However, the latter study was performed in a small number of subjects (6 adults) and bioavailability was estimated using the traditional noncompartmental approach after i.”
MethodChen, S., Yang, J.-J., Zhang, Y., Lei, L., Qiu, D., Lv, H.-M., Sun, Z., Hashimoto, K., & Yang, J. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01611-z · Cited by 32
“The plasma concentration of ketamine for analgesia ranges from 100 to 160 ng mL −1 [25, 26] and that for antidepressant action is approximately 185 ng mL −1 [27].”
Karami, A., Christianus, A., Ishak, Z., Syed, M. A., & Courtenay, S. C. (2011) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2011.05.012 · Cited by 29
Kaka, U., Chen, H. C., Meng, G. Y., Fakurazi, S., Kaka, A., Behan, A. A., & Ebrahimi, M. M. (2015) · BioMed Research International · doi:10.1155/2015/305367 · Cited by 37
“Effective analgesic plasma concentration of ketamine in humans ranges from 100 to 200 ng/mL [44].”
Kaka, U., Saifullah, B., Abubakar, A. A., Goh, Y. M., Fakurazi, S., Kaka, A., Behan, A. A., Ebrahimi, M. M., & Chen, H. C. (2016) · BMC Veterinary Research · doi:10.1186/s12917-016-0815-4 · Cited by 35
“This concurred with findings in humans, where serum concentration of 100–200 ng/mL of ketamine was reported to be analgesic with minimal side effects [11, 31].”
BackgroundResultOral Ketamine for Acute Pain Management After Amputation Surgery
Buvanendran, A., Kroin, J. S., Rajagopal, A., Robison, S. J., Moric, M. M., & Tuman, K. J. (2017) · Pain Medicine · doi:10.1093/pm/pnx229 · Cited by 27
Ketamine and the Disinhibition Hypothesis: Neurotrophic Factor-Mediated Treatment of Depression
Borsellino, P., Krider, R. I., Chea, D., Grinnell, R., & Vida, T. A. (2023) · Pharmaceuticals · doi:10.3390/ph16050742 · Cited by 33
“Subsequent reactions include hydroxylation of the cyclohexone ring, conjugation to glucuronic acid, and dehydration until ultimately clearing the body primarily in the urine [53,74].”
BackgroundGao, M., Sun, J., Jin, W., & Qian, Y. (2011) · Inflammation · doi:10.1007/s10753-011-9413-6 · Cited by 27
FOUR PREANESTHETIC ORAL SEDATION PROTOCOLS FOR RHESUS MACAQUES (MACACA MULATTA)
Pulley, A. C. S., Roberts, J. A., & Lerche, N. W. (2004) · Journal of Zoo and Wildlife Medicine · doi:10.1638/03-092 · Cited by 27
“497 Journal of Zoo and Wildlife Medicine 35(4): 497–502, 2004”
BackgroundEffects of somatic treatments on suicidal ideation and completed suicides
Hawkins, E. M., Coryell, W. H., Leung, S., Parikh, S. V., Weston, C. L., Nestadt, P. S., Nürnberger, J. I., Kaplin, A. I., Kumar, A., Farooqui, A. A., et al. (2021) · Brain and Behavior · doi:10.1002/brb3.2381 · Cited by 31
“The bioavailability of oral ketamine is very poor with less than 25% of administered oral dose reaching the venous circulation (Chong et al., 2009; Clements et al., 1982).”
BackgroundHassan, K., Struthers, W. M., Sankarabhotla, A., & Davis, P. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.992624 · Cited by 33
“Specifically, oral ketamine has been shown to undergo extensive first-pass metabolism and consequently has approximately 10–20% bioavailability, while SL ketamine has a bioavailability of approximately 30% (42, 43), a fact which must be taken into account when designing outpatient oral or SL ketamine treatment regimen…”
BackgroundKrenn, H., Deusch, E., Balogh, B., Jellinek, H., Oczenski, W., Plainer-Zöchling, E., & Fitzgerald, R. D. (2005) · European Journal of Anaesthesiology · doi:10.1017/s0265021503000048 · Cited by 26
Suzuki, M., Kinoshita, T., Kikutani, T., Yokoyama, K., Inagi, T., Sugimoto, K., Haraguchi, S., Hisayoshi, T., & Shimada, Y. (2005) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000166952.12290.45 · Cited by 28
Rubinstein, O., Barkan, S., Breitbart, R., Berkovitch, S., Toledano, M., Weiser, G., Karadi, N., Nassi, A., & Kozer, E. (2016) · Medicine · doi:10.1097/md.0000000000003984 · Cited by 25
The diverse effects of ketamine, jack-of-all-trades: a narrative review
Richards, N. D., Howell, S. J., Bellamy, M. C., & Beck, J. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.11.018 · Cited by 33
Wolfson, P. E., Cole, R., Lynch, K. L., Yun, C. A., Wallach, J. V., Andries, J., & Whippo, M. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2101903 · Cited by 24
Dwivedi, P., Patel, T. K., Bajpai, V., Singh, Y., Tripathi, A., & Kishore, S. (2022) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-022-02305-1 · Cited by 24
“Only about 17% of ketamine is absorbed from the oral route because of extensive firstpass metabolism as opposed to 93% from the parenteral route.(6) The bioavailability of ketamine is 45–55%(7) from the intranasal route compared with 30% from the sublingual route.”
BackgroundDifferential effects of NMDA receptor antagonism on spine density
Ruddy, R. M., Chen, Y., Milenkovic, M., & Ramsey, A. J. (2014) · Synapse · doi:10.1002/syn.21784 · Cited by 25
Oral ketamine as a positive control in human abuse potential studies
Shram, M. J., Sellers, E. M., & Romach, M. K. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.10.002 · Cited by 27
“This could explain some, but not all reportedfindings, particlarly considering that recreational ketamine users take quantities hat are far greater (Clements et al., 1982;Grant et al., 1981; Schmid t al., 1999).”
BackgroundColla, M., Offenhammer, B., Scheerer, H., Kronenberg, G., Vetter, S., Mutschler, J., Mikoteit, T., Bankwitz, A., Adank, A., Schaekel, L., et al. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.03.002 · Cited by 23
Reversible medetomidine/ketamine anesthesia in captive capuchin monkeys (Cebus apella)
Theriault, B. R., Reed, D., & Niekrasz, M. (2008) · Journal of Medical Primatology · doi:10.1111/j.1600-0684.2007.00267.x · Cited by 23
Comparison of the Effects of Ketamine and Morphine on Performance of Representative Military Tasks
Gaydos, S., Kelley, A. M., Grandizio, C. M., Athy, J. R., & Walters, P. L. (2014) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2014.06.047 · Cited by 22
Brain penetration of ketamine: Intranasal delivery VS parenteral routes of administraion
Naidoo, V., Mdanda, S., Ntshangase, S., Naicker, T., Kruger, H. G., Govender, T., Naidoo, P., & Baijnath, S. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.02.003 · Cited by 25
Recent Progress in Gels for Neuropathic Pain
Pușcașu, C., Zanfirescu, A., & Negreș, S. (2023) · Gels · doi:10.3390/gels9050417 · Cited by 26
Keavy, D., Bristow, L. J., Sivarao, D. V., Batchelder, M., King, D., Thangathirupathy, S., Macor, J. E., & Weed, M. R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152729 · Cited by 23
“Ketamine is rapidly eliminated from plasma after IV administration [24], and its EEG effects in humans closely follow its pharmacokinetic profile [25].”
BackgroundPopulation Pharmacokinetics of Intramuscular and Intravenous Ketamine in Children
Hornik, C. P. V., González, D., van den Anker, J. N., Atz, A. M., Yogev, R., Poindexter, B. B., Ng, K. C., Delmore, P., Harper, B., Melloni, C., et al. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1116 · Cited by 22
Bearn, J., & O'Brien, M. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.02.005 · Cited by 28
Brenna, C. T. A., Goldstein, B. I., Zarate, C. A., & Orser, B. A. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005037 · Cited by 24
Effect of low dose rate ketamine infusions on thermal and mechanical thresholds in conscious cats
Ambros, B., & Duke, T. (2013) · Veterinary Anaesthesia and Analgesia · doi:10.1111/vaa.12057 · Cited by 21
Pharmacokinetics and Pharmacology of Drugs Used in Children
Anderson, B. J., Lerman, J., & Coté, C. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-42974-0.00007-0 · Cited by 25
Kinetics of ketamine and its metabolites in rabbits with normal and impaired renal function
Pedraz, J. L., Lanao, J. M., & Domínguez‐Gil, A. (1985) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03189695 · Cited by 21
Winterborn, A., Bates, W., Feng, C., & Wyatt, J. D. (2007) · Journal of Medical Primatology · doi:10.1111/j.1600-0684.2007.00234.x · Cited by 21
Ketamine as Potential Treatment for Postpartum Depression: A Narrative Review
Chen-Li, D. C. J., Lui, L. M. W., Rosenblat, J. D., Lipsitz, O., Teopiz, K. M., Ho, R., Vinberg, M., Golts, M., Jawad, M. Y., Lee, Y. L., et al. (2022) · Annals of Clinical Psychiatry · doi:10.12788/acp.0082 · Cited by 21
From in vitro to in vivo: A comprehensive guide to IVIVC development for long-acting therapeutics
Pastorin, G., Benetti, C., & Wacker, M. G. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114906 · Cited by 23
Molecular pathways of ketamine: A systematic review of immediate and sustained effects on PTSD
Wellington, N. J., Bouças, A. P., Lagopoulos, J., Quigley, B. L., & Kuballa, A. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06756-4 · Cited by 25
“Ketamine can be detected in the blood for up to 24 h after administration, influenced by factors such as metabolism rate, dosage, and frequency of use (Clements et al. 1982).”
Carter, L. P. (2010) · Drug Testing and Analysis · doi:10.1002/dta.203 · Cited by 22
Oral Administration of Injectable Ketamine During Burn Wound Dressing Changes
Lintner, A. C., Brennan, P. G., Miles, M. V. P., Leonard, C., Alexander, K. M., & Kahn, S. A. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019876497 · Cited by 20
“Age (years) 32 (26-57) Sex (male:female) 11:3 Weight (kg) 87 (73-95) %TBSA 17 (12-41) Wound care sessions per patient (n) 3.”
Surjan, J., Grossi, J. D., Del Porto, J. A., Delfino, R. S., de Oliveira Cerqueira, R., Lucchese, A. C., Magalhães, E., Del Sant, L. C., Tuena, M. A., Nakahira, C., et al. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01193-z · Cited by 19
Carrara, L., Nault, M., Morisson, L., Godin, N., Idrissi, M., Fortier, A., Guertin, M. C., Brulotte, V., Fortier, L., Verdonck, O., et al. (2021) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000001588 · Cited by 23
Oral ketamine may offer a solution to the ketamine conundrum
Dutton, M., Can, A., Lagopoulos, J., & Hermens, D. F. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06480-x · Cited by 23
“Studies show blood concentrations of norketamine are substantially higher following oral administration than when administered by other routes (Clements and Nimmo 1981, Clements et al. 1982) and this may contribute to the efficacy observed in oral dosing.”
BackgroundInfluentialMaudlin, B., Gibson, S. B., & Aggarwal, A. K. (2021) · Internal Medicine Journal · doi:10.1111/imj.15404 · Cited by 19
“Page 4 reproducible to support its use in pain management [6-8; 26; 33].”
BackgroundMethodAdvanced Formulation Design: Improving Drug Therapies for the Management of Severe and Chronic Pain
Miller, D. A., DiNunzio, J. C., & Williams, R. O. (2008) · Drug Development and Industrial Pharmacy · doi:10.1080/03639040701542200 · Cited by 18
Investigational drug therapies in phase I and phase II clinical trials for alcohol use disorders
Walker, L. C., & Lawrence, A. J. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1502269 · Cited by 21
“nificant risk of abuse especially via injection, which preserves its bioavailability [50].”
BackgroundRemifentanil versus alfentanil in total intravenous anaesthesia for day case surgery
Alper, I., Erhan, E., Uğur, G., & Ozyar, B. (2005) · European Journal of Anaesthesiology · doi:10.1017/s0265021503000115 · Cited by 18
The role of NMDARs in the anesthetic and antidepressant effects of ketamine
Zhou, L., & Duan, J. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14464 · Cited by 17
“…Furthermore, the dissociative side effects of ketamine are acute and dissipate in 80 min, and the antidepressant effects occur within 110 min and last for 1 week, 66,67 suggesting that the ketamine-mediated dissociative side effects and antidepressant effects depend on diverse signaling pathways.”
BackgroundSaba, W., Goutal, S., Kühnast, B., Dollé, F., Auvity, S., Fontyn, Y., Cayla, J., Peyronneau, M., Valette, H., & Tournier, N. (2015) · European Journal of Neuroscience · doi:10.1111/ejn.12946 · Cited by 17
“Pharmacokinetic studies have reported a 3-h elimination halflife of ketamine in humans (Clements et al., 1982).”
BackgroundRovirosa-Hernández, M. D. J., García‐Orduña, F., Caba, M., Canales‐Espinosa, D., Hermida‐Lagunes, J., & Pelayo, V. D. R. T. (2011) · Journal of Medical Primatology · doi:10.1111/j.1600-0684.2011.00474.x · Cited by 17
Case Report: Efficacy and Tolerability of Ketamine in Opioid-Refractory Cancer Pain
Amin, P., Roeland, E. J., & Atayee, R. S. (2014) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.3109/15360288.2014.938881 · Cited by 17
Gibuła‐Tarłowska, E., Wiszniewska, A., Turyk, M., Szymczyk, P., Kotlinska, J. H., & Kędzierska, E. (2025) · Molecules · doi:10.3390/molecules30132824 · Cited by 22
“It was suggested that ketamine can provide a unique mental state that facilitates and enriches therapeutic experiences, which in turn may improve efficacy and lengthen treatment effects [35,95].”
Liu, H., Lan, X., Wang, C., Zhang, F., Fu, L., Li, W., Ye, Y., Hu, Z., Chao, Z., Ning, Y., et al. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04388-y · Cited by 18
“The bioavailability of oral ketamine is variable and low compared to intravenous ketamine, and the absorption rate of oral ketamine appears to vary considerably between and within patients [55, 56].”
BackgroundElectrocorticographic effects of acute ketamine on non-human primate brains
Yan, T., Suzuki, K., Kameda, S., Maeda, M., Mihara, T., & Hirata, M. (2022) · Journal of Neural Engineering · doi:10.1088/1741-2552/ac6293 · Cited by 16
“In terms of the terminal plasma half-life of ketamine, different administration methods (im or iv) showed no significant difference in human volunteers [70].”
The NMDA receptor antagonists memantine and ketamine as anti-migraine agents
Podkowa, K., Czarnacki, K., Borończyk, A., Borończyk, M., & Paprocka, J. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02444-2 · Cited by 21
Novel uses of ketamine in the emergency department
Corwell, B. N., Motov, S. M., Davis, N. L., & Kim, H. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2100883 · Cited by 16
“achieve peak plasma concentrations rapidly [18,22,44,45].”
BackgroundStress, mental disorder and ketamine as a novel, rapid acting treatment
Dutton, M., Can, A., Lagopoulos, J., & Hermens, D. F. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.09.006 · Cited by 18
Glutamate-Based Drug Discovery for Novel Antidepressants
Pałucha-Poniewiera, A., & Pilc, A. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1213234 · Cited by 17
“life in humans is 180 min [19]) and the antidepressant effects last”
BackgroundWang, R., Gan, J., Li, R., Duan, J., Zhou, J., Lv, M., & Qi, R. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101964 · Cited by 14
RetractedA dose‐escalation clinical trial of intranasal ketamine for uncontrolled cancer‐related pain
Singh, V., Gillespie, T. W., Lane, O. P., Spektor, B., Zarrabi, A. J., Egan, K., Curseen, K. A., Tsvetkova, M., Beumer, J. H., Sniecinski, R. M., et al. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2669 · Cited by 16
Watso, J. C., Huang, M. R., Hendrix, J. M., Belval, L. N., Moralez, G., Cramer, M. N., Foster, J., Hinojosa‐Laborde, C., & Crandall, C. G. (2023) · Prehospital Emergency Care · doi:10.1080/10903127.2023.2172493 · Cited by 15
“A second intravenous fentanyl/ketamine/placebo administration was made 30minutes after the initial administration because the circulating concentrations of fentanyl (56, 57) and ketamine (58, 59) are significantly reduced by 30minutes after administration.”
BackgroundKetamine in treating opioid use disorder and opioid withdrawal: a scoping review
Shen, M. R., Campbell, D. E., Kopczynski, A., Maddams, S., Rosenblum, N., Nigam, K. B., & Suzuki, J. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1552084 · Cited by 19
“%) due to extensive fi rst-pass metabolism (26, 27).”
CYP 450 enzymes influence (R,S)-ketamine brain delivery and its antidepressant activity
Nguyen, T. M. L., McGowan, J. C., & Gardier, A. M. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108936 · Cited by 17
Population pharmacokinetics of ketamine in children with heart disease
Elkomy, M. H., Drover, D. R., Hammer, G. B., Galinkin, J. L., & Ramamoorthy, C. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.11.026 · Cited by 14
Rodrigues, N. B., Chen-Li, D. C. J., Vincenzo, J. D. D., Juneja, A., Pinder, B. D., McIntyre, R. S., & Rosenblat, J. D. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241238284 · Cited by 13
“Comparatively, the foregoing study cannot be generalized to patients receiving oral ketamine, as the bioavailability is approximately 16% and ketamine is rapidly metabolized into norketamine and dehydronorketamine (Clements et al., 1982; Dinis-Oliveira, 2017).”
BackgroundRamiole, C., d’Hayer, B., Boudy, V., Legagneux, J., Fonsart, J., & Houzé, P. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.09.001 · Cited by 14
Ketamine induced cell death can be mediated by voltage dependent calcium channels in PC12 cells
Bustamante, J., Acosta, L. H., Karadayian, A. G., & Lores‐Arnaiz, S. (2019) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2019.104318 · Cited by 13
Matłoka, M., Janowska, S., Gajos‐Draus, A., Ziółkowski, H., Janicka, M., Perko, P., Kamil, K., Pankiewicz, P., Moszczyński-Pętkowski, R., Mach, M., et al. (2022) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2022.102127 · Cited by 14
Effects of ketamine constant rate infusions on cardiac biomarkers and cardiac function in dogs
Franco, L. G., Wilges, C. H. D. M., Daniel, P., Cerejo, S. A., Nishimura, L. T., & Bittar, I. P. (2017) · Veterinary Anaesthesia and Analgesia · doi:10.1016/j.vaa.2017.10.007 · Cited by 13
Practical Treatment Recommendations for the Safe Use of Anaesthetics
Sear, J. W. (1992) · Drugs · doi:10.2165/00003495-199243010-00006 · Cited by 16
Pharmacology of ketamine and esketamine as rapid-acting antidepressants
Pavlidi, P., Megalokonomou, A., Sofron, A., Kokras, N., & Dalla, C. (2021) · Psychiatriki · doi:10.22365/jpsych.2021.050 · Cited by 13
A molecular perspective on mGluR5 regulation in the antidepressant effect of ketamine
Elmeseiny, O. S. A., & Müller, H. K. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107081 · Cited by 14
Zuo, D., Liu, Y., Liu, Z., Cui, J., Zhou, X., Liu, Y., Li, Z., & Wu, Y. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.05.003 · Cited by 12
Severe Heloderma spp. envenomation: a review of the literature
Chippaux, J., & Amri, K. (2020) · Clinical Toxicology · doi:10.1080/15563650.2020.1853145 · Cited by 12
Metadata
- Authors
- Clements, J. A., Nimmo, W. S., & Grant, I. S.
- Affiliations
- Heriot-Watt University (GB)
- Western Infirmary (GB)
- Corresponding author
- Clements, J.A.
- ORCID
- Grant, I.S.
- Venue
- Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 1982-05
- Volume
- 71
- Issue
- 5
- Pages
- 539-542
- ISSN
- 0022-3549 (ISSN-L)
- OpenAlex
- W2094496261
- Cited by
- 420
- References
- 20
- Citations by year
- 2026: 20 · 2025: 25 · 2024: 17 · 2023: 20 · 2022: 34 · 2021: 17 · 2020: 50 · 2019: 11 · 2018: 20 · 2017: 13 · 2016: 20 · 2015: 16 · 2014: 21 · 2013: 16 · 2012: 10
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of Pharmaceutical Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- ketamine, pharmacokinetics, bioavailability, analgesia, pain threshold, first-pass metabolism, intramuscular injection, oral administration, intravenous administration, two-compartment model, terminal half-life
- MeSH terms
- Administration, Oral, Adult, Analgesics, Biological Availability, Physical Exertion, Humans, Injections, Intramuscular, Injections, Intravenous, Ketamine, Kinetics, Pain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.